Epic Sciences' Research in Prostate Cancer Presented at the 2013 ASCO Genitourinary Cancers Symposium
SAN DIEGO, California - 02/12/2013

SAN DIEGO and ORLANDO, FLA. - February 12, 2013 -- Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking place February 14 to 16 in Orlando, Fla.  The symposium presents the latest research in genitourinary cancers and is sponsored by three leading medical specialty societies: American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

The poster will be presented during General Poster Session A: Prostate Cancer on Thursday, February 14 from 11:45 am to 1:15 pm EST in Gatlin Ballroom B.  Additional presentation details are as follows:

Abstract Number: 62

Poster Title: Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC).

Authors: Elizabeth Punnoose, Eric Tucker, Dena Marrinucci, Edith Szafer-Glusman, Lukas Amler, Hartmut Koeppen, Premal Patel, Gerhardt Attard, Johann De Bono

Poster Number: D17

About Circulating Tumor Cells (CTCs)

CTCs are cells that escape from solid tumors, enter the bloodstream where they travel and eventually cause cancer metastasis. Today, solid cancers are first detected by invasive biopsies, which cannot be used repeatedly and may be ineffective in understanding metastatic risk, disease progression, treatment effectiveness and recurrence identification. A blood test that can accurately detect and profile biomarkers on CTCs is easy to conduct frequently and should be able to provide essential, real-time information about disease status to tailor treatments to a patient's specific cancer and response.

About Epic Sciences

Epic Sciences, Inc. is a privately held company that is developing new diagnostic tests to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic has partnered with numerous pharmaceutical companies, major cancer centers, the National Cancer Institute (NCI) and the National Institutes of Health (NIH), to advance this technology to improve clinical oncology and cancer therapeutic development. With these collaborations, Epic is developing a robust commercial platform with a strong and diverse pipeline of companion diagnostic products. For more information, please visit http://www.epicsciences.com . 

For Media Only:                                                       

Jessica Yingling, Ph.D.

Little Dog Communications

858.344.8091

[email protected]